Biomedical company Inovio has announced that its SynCon H1N1 influenza DNA vaccine has achieved 100% protection against swine origin influenza A/H1N1 viruses in animal studies.
In the second study for the vaccine, mice immunised with A/H1N1 vaccine components recovered from virus infection-induced morbidity significantly faster than the non-immunised control animals.
In a previous study, the Inovio team demonstrated that mice immunised with the SynCon H1N1 DNA vaccine provided 100% protection in a lethal challenge study against H1N1 virus.
Inovio CEO Joseph Kim said that the latest data further underscores the potential of the SynCon technology to create vaccines capable of protecting against emerging pandemic influenza viruses.
“Our SynCon influenza vaccines were developed prior to the emergence of the current swine flu strains and have yielded strong protective responses in animal models against a variety of unmatched influenza strains,” Kim said.
Inovio is one of the first pharmaceutical companies to report on the successful protection of vaccinated animals against the 2009 influenza A/H1N1 virus, as well as the first to report on preclinical results using pigs, a more natural host for the virus.
The company had previously reported data from an ongoing study in a pig model, in which the SynCon-based H1N1 vaccines achieved haemagglutination inhibition titers above the protection threshold in 100% of the vaccinated animals against the swine influenza virus.